New Key Statistics Module, Z-Score and F-Score
NAS:CALT Key Ratios
| Market Cap $ M | 1,080.80 |
| Enterprise Value $ M | 1,101.55 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 6.33 |
| Price/Book | 104.40 |
| Price/Sales | 6.92 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 152.00 |
| EPS (TTM) $ | -1.68 |
| Beneish M-Score | -2.87 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -36.20 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -31.23 |
| EV-to-EBITDA | -31.23 |
| PEG | -- |
| Shares Outstanding M | 27.02 |
| Net Margin (%) | -30.00 |
| Operating Margin % | -24.32 |
| Pre-tax Margin (%) | -29.24 |
| Quick Ratio | 2.59 |
| Current Ratio | 2.69 |
| ROA % (ttm) | -27.88 |
| ROE % (ttm) | -169.32 |
| ROIC % (ttm) | -64.74 |
| Dividend Yield % | -- |
| Altman Z-Score | 4.83 |
CALT Number of Guru Trades
CALT Volume of Guru Trades
Gurus Latest Trades with NAS:CALT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CALT is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Calliditas Therapeutics AB Insider Transactions
No Available Data
News about NAS:CALT
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers